BACKGROUND: Long-term cognitive impairment has been reported in adult bone marrow transplant (BMT) recipients. However, the degree to which such impairment is attributable to the procedure or is a condition existing before BMT is not known. METHODS: The presence, nature, and correlates of neuropsychologic impairment were investigated in 55 adult BMT candidates, all of whom had a malignant condition. Impairment was assessed using a screening battery of standardized neuropsychologic tests. RESULTS: Results indicated that: (1) neuropsychologic performance was associated with specific disease and treatment risk factors, in particular a history of cranial radiation or central nervous system disease treated with intrathecal chemotherapy; (2) performance on tests reflecting memory or higher cognitive processing was more likely to be impaired; and (3) the risk of impairment increased as the number of disease and treatment risk factors for cognitive impairment in the patient increased. CONCLUSIONS: It was concluded that neuropsychologic impairment occurs in a significant minority of adult patients before BMT. Research is necessary to determine the extent to which such impairment significantly compromises patients' abilities to: (1) make decisions regarding undergoing BMT or participating in research protocols and (2) understand and execute self-care behaviors after BMT. More broadly, greater attention should be devoted to investigating the presence of long-term neuropsychologic impairment in adult patients with cancer.
BACKGROUND: Long-term cognitive impairment has been reported in adult bone marrow transplant (BMT) recipients. However, the degree to which such impairment is attributable to the procedure or is a condition existing before BMT is not known. METHODS: The presence, nature, and correlates of neuropsychologic impairment were investigated in 55 adult BMT candidates, all of whom had a malignant condition. Impairment was assessed using a screening battery of standardized neuropsychologic tests. RESULTS: Results indicated that: (1) neuropsychologic performance was associated with specific disease and treatment risk factors, in particular a history of cranial radiation or central nervous system disease treated with intrathecal chemotherapy; (2) performance on tests reflecting memory or higher cognitive processing was more likely to be impaired; and (3) the risk of impairment increased as the number of disease and treatment risk factors for cognitive impairment in the patient increased. CONCLUSIONS: It was concluded that neuropsychologic impairment occurs in a significant minority of adult patients before BMT. Research is necessary to determine the extent to which such impairment significantly compromises patients' abilities to: (1) make decisions regarding undergoing BMT or participating in research protocols and (2) understand and execute self-care behaviors after BMT. More broadly, greater attention should be devoted to investigating the presence of long-term neuropsychologic impairment in adult patients with cancer.
Authors: Heather S L Jim; Brent Small; Sheri Hartman; Jamie Franzen; Shannon Millay; Kristin Phillips; Paul B Jacobsen; Margaret Booth-Jones; Joseph Pidala Journal: Cancer Date: 2011-12-02 Impact factor: 6.860
Authors: Kristine A Donovan; Brent J Small; Michael A Andrykowski; Frederick A Schmitt; Pamela Munster; Paul B Jacobsen Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: D D Correa; J C Root; R Baser; D Moore; K K Peck; E Lis; T B Shore; H T Thaler; A Jakubowski; N Relkin Journal: Brain Imaging Behav Date: 2013-12 Impact factor: 3.978
Authors: D D Correa; Y Wang; J D West; K K Peck; J C Root; R E Baser; H T Thaler; T B Shore; A Jakubowski; A J Saykin; N Relkin Journal: Brain Imaging Behav Date: 2016-06 Impact factor: 3.978
Authors: Heather S L Jim; Kristine A Donovan; Brent J Small; Michael A Andrykowski; Pamela N Munster; Paul B Jacobsen Journal: Cancer Date: 2009-04-15 Impact factor: 6.860
Authors: Desiree Jones; Elisabeth G Vichaya; Xin Shelley Wang; Mary H Sailors; Charles S Cleeland; Jeffrey S Wefel Journal: Cancer Date: 2013-09-16 Impact factor: 6.860
Authors: Mary-Ellen Meadows; Grace Chang; Jennifer A Jones; Joseph R Antin; E John Orav Journal: Arch Clin Neuropsychol Date: 2013-02-07 Impact factor: 2.813
Authors: James R Basinski; Catherine M Alfano; Wayne J Katon; Karen L Syrjala; Jesse R Fann Journal: Biol Blood Marrow Transplant Date: 2010-01-25 Impact factor: 5.742